OverviewSuggest Edit

Oramed Pharmaceuticals is a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

TypePublic
Founded2006
HQNew York, NY, US
Websiteoramed.com

Latest Updates

Employees (est.) (Nov 2017)14(+17%)
Revenue (FY, 2019)$2.7 M(+11%)
Share Price (Jun 2021)$12.1
Cybersecurity ratingBMore

Key People/Management at Oramed Pharmaceuticals

Nadav Kidron

Nadav Kidron

Chief Executive Officer, President & Director
Miriam Kidron

Miriam Kidron

Chief Scientific Officer & Director
Josh Hexter

Josh Hexter

Chief Operating and Business Officer
Avi Gabay

Avi Gabay

CFO
Show more

Oramed Pharmaceuticals Office Locations

Oramed Pharmaceuticals has offices in New York, ירושלים and Jerusalem
New York, NY, US (HQ)
1185 6th Ave #228
ירושלים, IL (HQ)
Hi-Tech Park
Jerusalem, IL
8, ALROV MAMILLA AVENUE
Show all (3)

Oramed Pharmaceuticals Financials and Metrics

Oramed Pharmaceuticals Revenue

Oramed Pharmaceuticals's revenue was reported to be $2.7 m in FY, 2019
USD

Revenue (Q1, 2021)

674.0k

Market capitalization (4-Jun-2021)

371.5m

Closing stock price (4-Jun-2021)

12.1

Cash (30-Nov-2020)

14.9m

EV

357.2m
Oramed Pharmaceuticals's current market capitalization is $371.5 m.
Annual
USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

641.0k2.5m2.4m2.7m

Cost of goods sold

490.0k187.0k90.0k

Gross profit

151.0k2.3m2.6m

Gross profit Margin, %

24%92%97%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

125.0k163.0k(610.0k)611.0k(617.0k)611.0k604.0k617.0k674.0k666.0k682.0k674.0k674.0k681.0k674.0k

Cost of goods sold

187.0k86.0k35.0k55.0k

Gross profit

(797.0k)531.0k639.0k611.0k

Gross profit Margin, %

131%86%95%92%
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m2.3m3.2m3.9m4.0m5.0m3.3m

Accounts Receivable

87.7k58.4k

Prepaid Expenses

2.3k90.1k127.0k198.0k159.0k574.0k1.0m

Current Assets

5.3m8.6m17.4m31.2m20.3m31.0m33.3m
Quarterly
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(4.2m)(5.7m)(11.0m)(10.5m)(12.7m)(14.4m)

Depreciation and Amortization

14.7k5.4k6.0k4.0k4.0k5.0k6.0k8.0k

Accounts Payable

203.1k(146.2k)475.0k

Cash From Operating Activities

(2.3m)(3.4m)(4.1m)(4.9m)4.7m(5.8m)(14.7m)(12.9m)
USDQ1, 2012

Financial Leverage

1.2 x
Show all financial metrics

Oramed Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Oramed Pharmaceuticals Online and Social Media Presence

Embed Graph

Oramed Pharmaceuticals News and Updates

Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HJLI, ORMP, TLRY, HEXO, and ABUS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oramed Pharmaceuticals Issues Letter to Shareholders

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief...

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the...

Oramed Pharmaceuticals Blogs

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

First and Largest of two concurrent Phase 3 trials on track to complete randomization by Q4 2021 NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery s…

CNBC: CEO says oral vaccines for Covid will help cut down logistical challenges and waste

CEO Nadav Kidron spoke to CNBC's Capital  Connection about Oramed's new venture, Oravax Medical and bringing an oral Covid-19 vaccine to market. He spoke about how an oral vaccine will help cut down logistical challenges and waste and how it will be an “essential product” if regular boosters are nee…

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand R…

CEO Nadav Kidron on the TD Ameritrade Network

CEO Nadav Kidron talks to Nicole Petallides of TD Ameritrade's The Watch about $ORMP's Covid-19 oral vaccine developments and progress on oral insulin for diabetes.  Watch here. The post CEO Nadav Kidron on the TD Ameritrade Network appeared first on Oramed Pharmaceuticals.

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol

Patients screened in ORA-D-013-2 study which is recruiting 450 patients in 53 sites in the U.S., Europe and Israel NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of …

Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

ORA-D-013-1 study is recruiting 675 patients through 75 clinical sites throughout the U.S. NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, anno…
Show more

Oramed Pharmaceuticals Frequently Asked Questions

  • When was Oramed Pharmaceuticals founded?

    Oramed Pharmaceuticals was founded in 2006.

  • Who are Oramed Pharmaceuticals key executives?

    Oramed Pharmaceuticals's key executives are Nadav Kidron, Miriam Kidron and Josh Hexter.

  • How many employees does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 14 employees.

  • What is Oramed Pharmaceuticals revenue?

    Latest Oramed Pharmaceuticals annual revenue is $2.7 m.

  • What is Oramed Pharmaceuticals revenue per employee?

    Latest Oramed Pharmaceuticals revenue per employee is $193.1 k.

  • Who are Oramed Pharmaceuticals competitors?

    Competitors of Oramed Pharmaceuticals include Rani Therapeutics, Viatris and BIOTON.

  • Where is Oramed Pharmaceuticals headquarters?

    Oramed Pharmaceuticals headquarters is located at 1185 6th Ave #228, New York.

  • Where are Oramed Pharmaceuticals offices?

    Oramed Pharmaceuticals has offices in New York, ירושלים and Jerusalem.

  • How many offices does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 3 offices.